NANO MRNA Co.,Ltd.
4571 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 港区愛宕二丁目５番１号
- Website:
- https://www.nanomrna.co.jp/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
NANO MRNA Co., Ltd. is a pioneering Japanese biotechnology company focused on advancing mRNA-based therapeutics. Evolving from its predecessor, NanoCarrier, the firm aims to establish a robust framework for drug discovery by connecting innovative research with medical needs. NANO MRNA is actively developing mRNA medicines, including those targeting conditions like glioblastoma and osteoarthritis. The company is engaged in both research and commercialization efforts, having launched products like the antimicrobial ear-nose-throat treatment Comrex®. With a commitment to innovation and global collaboration, NANO MRNA seeks to enhance the acceptance and application of mRNA technology in various medical fields, positioning itself at the forefront of next-generation therapies.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-18 08:30 |
Inside Information Statement
臨時報告書
|
Japanese | 28.4 KB | |
| 2025-07-01 08:30 |
Inside Information Statement
臨時報告書
|
Japanese | 25.9 KB | |
| 2025-06-30 08:33 |
Internal Control over Financial Reporting
内部統制報告書－第29期(2024/04/01－2025/03/31)
|
Japanese | 22.8 KB | |
| 2025-06-30 08:31 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2025-06-30 08:30 |
Annual Report
有価証券報告書－第29期(2024/04/01－2025/03/31)
|
Japanese | 906.3 KB | |
| 2025-05-14 08:34 |
Inside Information Statement
臨時報告書
|
Japanese | 18.7 KB | |
| 2025-02-14 07:38 |
Inside Information Statement
臨時報告書
|
Japanese | 18.8 KB | |
| 2024-11-18 07:32 |
Inside Information Statement
臨時報告書
|
Japanese | 18.6 KB | |
| 2024-11-14 07:03 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-11-14 07:02 |
Interim Report
半期報告書－第29期(2024/04/01－2025/03/31)
|
Japanese | 169.1 KB | |
| 2024-07-01 08:07 |
Inside Information Statement
臨時報告書
|
Japanese | 22.2 KB | |
| 2024-06-28 08:06 |
Internal Control over Financial Reporting
内部統制報告書－第28期(2023/04/01－2024/03/31)
|
Japanese | 22.1 KB | |
| 2024-06-28 08:05 |
Regulatory News Service
確認書
|
Japanese | 8.5 KB | |
| 2024-06-28 08:01 |
Annual Report
有価証券報告書－第28期(2023/04/01－2024/03/31)
|
Japanese | 922.0 KB | |
| 2024-02-14 07:05 |
Regulatory News Service
確認書
|
Japanese | 8.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP | |
| ASKA Pharmaceutical Holdings CO., Ltd. | Japan | 4886 | ||
|
Astellas Pharma Inc. | Japan | 4503 | |
|
AstraZeneca PLC | United Kingdom | AZN | |
|
Basilea Pharmaceutica AG | Switzerland | BSLN | |
|
Bayer AG | Germany | BAY | |
|
Biofarm S.A. | Romania | BIO | |
|
Biogened Spolka Akcyjna | Poland | BGD |